The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Tuberculosis (TB) Treatment Market Research Report 2025
Synopsis
If you have latent tuberculosis, you may need to take only one or two types of TB drug. Active tuberculosis, particularly if it's a drug-resistant strain, will require several drugs at once. The most common medications used to treat tuberculosis include:
Isoniazid
Rifampin (Rifadin, Rimactane)
Ethambutol (Myambutol)
Pyrazinamide
The global Tuberculosis (TB) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tuberculosis (TB) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tuberculosis (TB) Treatment.
Report Scope
The Tuberculosis (TB) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tuberculosis (TB) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tuberculosis (TB) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson
Otsuka Pharmaceutical Co., Ltd
Macleods Pharmaceutical Ltd
Dong-A ST Co., Ltd
Lupin Ltd
Janssen Products, LP
Mylan
Sanofi
Segment by Type
Isoniazid
Rifampin (Rifadin, Rimactane)
Ethambutol (Myambutol)
Pyrazinamide
Segment by Application
Active TB
Latent TB
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tuberculosis (TB) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
If you have latent tuberculosis, you may need to take only one or two types of TB drug. Active tuberculosis, particularly if it's a drug-resistant strain, will require several drugs at once. The most common medications used to treat tuberculosis include:
Isoniazid
Rifampin (Rifadin, Rimactane)
Ethambutol (Myambutol)
Pyrazinamide
The global Tuberculosis (TB) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tuberculosis (TB) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tuberculosis (TB) Treatment.
Report Scope
The Tuberculosis (TB) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tuberculosis (TB) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tuberculosis (TB) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson
Otsuka Pharmaceutical Co., Ltd
Macleods Pharmaceutical Ltd
Dong-A ST Co., Ltd
Lupin Ltd
Janssen Products, LP
Mylan
Sanofi
Segment by Type
Isoniazid
Rifampin (Rifadin, Rimactane)
Ethambutol (Myambutol)
Pyrazinamide
Segment by Application
Active TB
Latent TB
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tuberculosis (TB) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tuberculosis (TB) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Isoniazid
1.2.3 Rifampin (Rifadin, Rimactane)
1.2.4 Ethambutol (Myambutol)
1.2.5 Pyrazinamide
1.3 Market by Application
1.3.1 Global Tuberculosis (TB) Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Active TB
1.3.3 Latent TB
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tuberculosis (TB) Treatment Market Perspective (2019-2030)
2.2 Tuberculosis (TB) Treatment Growth Trends by Region
2.2.1 Global Tuberculosis (TB) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Tuberculosis (TB) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Tuberculosis (TB) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Tuberculosis (TB) Treatment Market Dynamics
2.3.1 Tuberculosis (TB) Treatment Industry Trends
2.3.2 Tuberculosis (TB) Treatment Market Drivers
2.3.3 Tuberculosis (TB) Treatment Market Challenges
2.3.4 Tuberculosis (TB) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tuberculosis (TB) Treatment Players by Revenue
3.1.1 Global Top Tuberculosis (TB) Treatment Players by Revenue (2019-2024)
3.1.2 Global Tuberculosis (TB) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Tuberculosis (TB) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tuberculosis (TB) Treatment Revenue
3.4 Global Tuberculosis (TB) Treatment Market Concentration Ratio
3.4.1 Global Tuberculosis (TB) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tuberculosis (TB) Treatment Revenue in 2023
3.5 Tuberculosis (TB) Treatment Key Players Head office and Area Served
3.6 Key Players Tuberculosis (TB) Treatment Product Solution and Service
3.7 Date of Enter into Tuberculosis (TB) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tuberculosis (TB) Treatment Breakdown Data by Type
4.1 Global Tuberculosis (TB) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Tuberculosis (TB) Treatment Forecasted Market Size by Type (2025-2030)
5 Tuberculosis (TB) Treatment Breakdown Data by Application
5.1 Global Tuberculosis (TB) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Tuberculosis (TB) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Tuberculosis (TB) Treatment Market Size (2019-2030)
6.2 North America Tuberculosis (TB) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Tuberculosis (TB) Treatment Market Size by Country (2019-2024)
6.4 North America Tuberculosis (TB) Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tuberculosis (TB) Treatment Market Size (2019-2030)
7.2 Europe Tuberculosis (TB) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Tuberculosis (TB) Treatment Market Size by Country (2019-2024)
7.4 Europe Tuberculosis (TB) Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tuberculosis (TB) Treatment Market Size (2019-2030)
8.2 Asia-Pacific Tuberculosis (TB) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Tuberculosis (TB) Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Tuberculosis (TB) Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tuberculosis (TB) Treatment Market Size (2019-2030)
9.2 Latin America Tuberculosis (TB) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Tuberculosis (TB) Treatment Market Size by Country (2019-2024)
9.4 Latin America Tuberculosis (TB) Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tuberculosis (TB) Treatment Market Size (2019-2030)
10.2 Middle East & Africa Tuberculosis (TB) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Tuberculosis (TB) Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Tuberculosis (TB) Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Tuberculosis (TB) Treatment Introduction
11.1.4 Johnson & Johnson Revenue in Tuberculosis (TB) Treatment Business (2019-2024)
11.1.5 Johnson & Johnson Recent Development
11.2 Otsuka Pharmaceutical Co., Ltd
11.2.1 Otsuka Pharmaceutical Co., Ltd Company Detail
11.2.2 Otsuka Pharmaceutical Co., Ltd Business Overview
11.2.3 Otsuka Pharmaceutical Co., Ltd Tuberculosis (TB) Treatment Introduction
11.2.4 Otsuka Pharmaceutical Co., Ltd Revenue in Tuberculosis (TB) Treatment Business (2019-2024)
11.2.5 Otsuka Pharmaceutical Co., Ltd Recent Development
11.3 Macleods Pharmaceutical Ltd
11.3.1 Macleods Pharmaceutical Ltd Company Detail
11.3.2 Macleods Pharmaceutical Ltd Business Overview
11.3.3 Macleods Pharmaceutical Ltd Tuberculosis (TB) Treatment Introduction
11.3.4 Macleods Pharmaceutical Ltd Revenue in Tuberculosis (TB) Treatment Business (2019-2024)
11.3.5 Macleods Pharmaceutical Ltd Recent Development
11.4 Dong-A ST Co., Ltd
11.4.1 Dong-A ST Co., Ltd Company Detail
11.4.2 Dong-A ST Co., Ltd Business Overview
11.4.3 Dong-A ST Co., Ltd Tuberculosis (TB) Treatment Introduction
11.4.4 Dong-A ST Co., Ltd Revenue in Tuberculosis (TB) Treatment Business (2019-2024)
11.4.5 Dong-A ST Co., Ltd Recent Development
11.5 Lupin Ltd
11.5.1 Lupin Ltd Company Detail
11.5.2 Lupin Ltd Business Overview
11.5.3 Lupin Ltd Tuberculosis (TB) Treatment Introduction
11.5.4 Lupin Ltd Revenue in Tuberculosis (TB) Treatment Business (2019-2024)
11.5.5 Lupin Ltd Recent Development
11.6 Janssen Products, LP
11.6.1 Janssen Products, LP Company Detail
11.6.2 Janssen Products, LP Business Overview
11.6.3 Janssen Products, LP Tuberculosis (TB) Treatment Introduction
11.6.4 Janssen Products, LP Revenue in Tuberculosis (TB) Treatment Business (2019-2024)
11.6.5 Janssen Products, LP Recent Development
11.7 Mylan
11.7.1 Mylan Company Detail
11.7.2 Mylan Business Overview
11.7.3 Mylan Tuberculosis (TB) Treatment Introduction
11.7.4 Mylan Revenue in Tuberculosis (TB) Treatment Business (2019-2024)
11.7.5 Mylan Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Tuberculosis (TB) Treatment Introduction
11.8.4 Sanofi Revenue in Tuberculosis (TB) Treatment Business (2019-2024)
11.8.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
